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a b s t r a c t
A selective method for the quantitation of pantoprazole and its metabolite in goat plasma was developed and
validated. Chloroform was used for drug extraction and separation occurred on a Symmetry C18 column. A combination of sodium phosphate dibasic (0.1 M, pH 7.5) and acetonitrile were used as the mobile phase (64:36, v/v)
while absorbance was measured at 290 nm. With a sample size of 0.1 mL the lower limit of quantiﬁcation (LLOQ)
was 0.01 μg/mL. The intra-assay variability for pantoprazole ranged from 3.4 to 10% while the metabolite ranged
from 3.3% to 8.7% The inter-assay variability ranged from 2.6 to 9.7% and 3.3 to 7.5% for pantoprazole and
its metabolite. The recovery was over 95% for both pantoprazole and its metabolite, pantoprazole sulfone. The
method was used to quantify both pantoprazole and its metabolite and was useful for pharmacokinetic studies.

1. Introduction
Pantoprazole is a proton pump inhibitor (PPI) that functions by irreversibly binding to the hydrogen pumps in the gastric parietal cells
which results in reduced gastric acid production. In veterinary medicine
the PPIs have been recognized as the most potent suppressor of gastric
acid [1].
Abomasal ulceration is a common morbidity observed in ruminant
species undergoing stress or hospitalization [1–3]. Pantoprazole is used
in ruminant practice for the increase of abomasal gastric pH and as a
therapeutic treatment for gastric ulceration [3,4]. Pantoprazole is not
currently labelled for use in any ruminant food animal species, and while
the usage of this drug is allowable under extralabel dosing provisions,
accurate analytical methods are necessary to guide clinicians regarding
the potential for accumulation and the pharmacokinetics of the drug
when considering its use in a food animal.
The majority of methods used to determine pantoprazole concentrations in plasma involve ultraviolet (UV) detection [5–10] or mass spectrometry (MS) [11–14]. Certain UV methods require 1 mL of sample
[6,7,10] while others require 0.5 mL [8,9]. The recovery of these methods ranged from 46 to 86% which is much lower than the method presented in this paper. The Xie method [5] has an LLOQ of 0.025 μg/mL,
is less accurate and has a longer run time. One method [8] requires a
complex switching technique and has a time-consuming complex extraction which only produces 75% sample recovery and a 0.2 μg/mL LLOQ.
While another method [12] requires the use of an expensive robotic liq-

∗

uid handling workstation and the samples must be frozen for at least
60 min as part of the extraction process. Both the Li et al. [11] and
Challa et al. [13] methods have a lower LOQ and use a smaller sample size however, both methods use a MS detector. The recovery of
the Li method [11] is 87% (78.6–109.7%) while the recovery for the
Challa et al. [13] method is not listed and neither method quantitates
the metabolite. The Olivarez method [14] used a 100 μl sample size
and had and average recovery of 98% which is similar to ours and their
LLOQ is 10 ng/mL which is the same as our LLOQ however they used an
LC MS/MS in order to achieve those results and did not quantitate the
metabolite. Two of the methods [6,10] require the use of ether for the extraction of 1 mL of plasma which produced a higher LLOQ (0.02 μg/mL)
and lower recoveries (46% and 86%). Neither method quantitates the
metabolite.
The intention of the study was to develop a precise, reliable, and
sensitive technique for the quantitation of pantoprazole and its metabolite in small volume samples. The technique has been used for sample
analysis from a goat pharmacokinetic study after administration of pantoprazole.
2. Material and methods
2.1. Chemicals and standards
Pantoprazole was purchased from Cayman Chemical (Ann Arbor,
MI), pantoprazole sulfone was purchased from Toronto Research Chemicals (Toronto, ON) and tinidazole was purchased from Sigma Chemical
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Fig. 1. Molecular structures of pantoprazole, pantoprazole sulfone and tinidazole.

(St. Louis, MO). The purity of all three chemicals (Fig. 1) was ≥99%.
All other chemicals and solvents were purchased from Fisher Scientiﬁc
(Pittsburgh, PA) and were HPLC grade.
Pantoprazole (100 μg/mL), pantoprazole sulfone (100 μg/mL) and
tinidazole (100 μg/mL, internal standard) were made by weighing the
appropriate amount and dissolving in methanol. Working stock solutions of pantoprazole and pantoprazole sulfone in methanol (0.1, 1 and
10 μg/mL) were prepared from stock solutions. All solutions were maintained in a −200 C freezer.
Standards and quality control samples were made by pipetting appropriate amounts of the stocks into tubes, evaporating with nitrogen
and then adding 100 μL of untreated goat plasma. There were 12 standards used in the composition of the curve, which ranged from 0.01 to
50 μg/mL. The quality control standards were 0.03, 0.3, 3 and 30 μg/mL.

2.4.1. Selectivity
The selectivity of the technique was based on analyzing plasma from
six diﬀerent goats that had not been treated with pantoprazole to determine if there were any interfering components from the matrix near the
elution times of pantoprazole, its metabolite and tinidazole.

2.2. Chromatographic equipment and conditions

2.4.3. Recovery accuracy and precision
Accuracy and precision were estimated by analyzing low
(0.03 μg/mL) medium (0.3 and 3 μg/mL) and high (30 μg/mL)
pantoprazole and metabolite concentrations. Five replicates of each
QC were assessed during a single run and on ﬁve diﬀerent days, from
that, the intra and inter-assay means, relative standard deviation (RSD)
and standard deviation (SD) were determined. The mean value could
not exceed ±15% of the actual value except for the lower limit of
quantiﬁcation (LLOQ), which should be reproducible with a precision
of 20%. Recovery was calculated as the percentage of the drug response
after extraction compared to the response of the drug in the standard
solution at a known concentration.

2.4.2. Linearity and calibration curve
The linearity of the plasma peak area ratio versus concentration
(0.01–50 μg/mL) was accepted if the correlation coeﬃcient was >0.99.
The calibration curve was constructed using the following points: 0.01,
0.025, 0.05, 1, 2.5, 5, 10, 25 and 50 μg/mL. The curves were produced
using the ratio of the peak area of pantoprazole or its metabolite divided by the peak area of tinidazole versus the concentration and were
generated on ﬁve diﬀerent days.

The equipment used for pantoprazole analysis consisted of a 2695
separation module and a 2487 UV detector (Waters, Milford, MA). A
Waters Symmetry C18 column (4.6 × 150 mm, 5 μm) was used for the
separation of the compounds. Sodium phosphate dibasic (0.1 M, pH 7.5)
and acetonitrile were used as the mobile phase (64:36, v/v) in the isocratic elution of the compounds. The ﬂow rate was 1.0 mL/min and the
UV detector was set to 290 nm. The column temperature was ambient
which was 22 ºC.
2.3. Sample preparation

2.4.4. Stability
The stability of the technique was estimated by using the four QC
samples. The samples were evaluated after three freeze/thaw cycles,
short term stability after extraction and storage in the autosampler for
24 h and after storage in a refrigerator (4 ºC) for 24 h.

Previously frozen samples were thawed at room temperature and
100 μl of plasma was added to a 13 × 100 mm screw top tube followed
by 10 μl of tinidazole (100 μg/mL, internal standard) and 2 mL chloroform. The mixture was rocked for 10 min and then underwent centrifugation for 10 min at 1000 × g. The chloroform layer was removed and
placed in a 16 × 100 mm tube and evaporated to dryness. Samples were
reconstituted in 250 μL of mobile phase and 100 μL was analyzed.

3. Results and discussion
3.1. HPLC optimization

2.4. Validation of analytical method
Acetonitrile was selected over methanol as the organic component
of the mobile phase due to reduced system pressure and better peak resolution. Because of previous experience with drugs of similar structure

The validation techniques used were based on FDA bioanalytical
guidelines [15].
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Table 1
Pantoprazole (Pan) and pantoprazole sulfone (PS) validation parameters in goat plasma (n = 5).
Intra-assay variability
Concentration (μg/mL)
0.03
0.30
3.0
30
Inter-assay variability
0.03
0.30
3.0
30

Pan Measured conc. (mean ± SD)
0.03 ± 0.003
0.33 ± 0.03
3.0 ± 0.10
30.8 ± 1.98

Pan Accuracy (%)
100
110
100
103

Pan RSD (%)
10.0
9.0
3.4
6.4

PS Measured conc. (mean ± SD)
0.03 ± 0.002
0.32 ± 0.01
3.2 ± 0.17
30.1 ± 0.99

PS Accuracy (%)
100
106
106
100

PS RSD (%)
8.7
4.3
5.2
3.3

0.03 ± 0.003
0.31 ± 0.01
3.0 ± 0.12
30.1 ± 0.70

100
103
100
100

9.8
4.3
3.9
2.3

0.03 ± 0.001
0.34 ± 0.02
3.0 ± 0.23
30.4 ± 1.0

100
113
100
101

3.4
7.2
7.5
3.3

n: number of samples; SD: standard deviation; RSD: relative standard deviation.

Fig. 2. Chromatograms for pantoprazole and pantoprazole sulfone in goat plasma. (A) untreated goat sample (B) 0.5 μg/mL standard (C) goat sample 20 min after
an intravenous dose (1 mg/kg) of pantoprazole.

sodium acetate and sodium phosphate were tested as the aqueous component of the mobile phase. Sodium phosphate produced the optimal
response and peak shape. After looking at 3.5, 5.5 and 7.5, the optimal
pH was determined to be 7.5. Sample injection volumes between 25 and
100 μL were tested and 100 μL provided the necessary sensitivity for the
sample size used.
The system suitability criteria used for pantoprazole and its metabolite included: column eﬃciency, resolution, retention time and USP tailing factor [16]. Column eﬃciency was established by determining the
theoretical plate number (N) which was 6444 and 5276 (N ≥ 2000)
for pantoprazole and the metabolite. Resolution, which is a measure
of how well peaks are separated was 8.01 and 6.15 (R ≥ 2) for pan-

toprazole and its metabolite. The retention times were 5.86 ± 0.04 and
4.49 ± 0.03 min for pantoprazole and pantoprazole sulfone and the USP
tailing factor was 1.21 and 1.28 (T ≤ 2).
3.2. Sample optimization
During the development of the technique several organic solvents
were evaluated including, acetonitrile, chloroform, hexane, methylene
chloride and methanol. Acetonitrile and methanol protein precipitation
required an extra step in order to reduce the turbidity of the supernatant
so that it could be injected. Hexane and methylene chloride produced
recoveries that were less than 50%. Chloroform produced an average
3
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Table 2
Recovery for pantoprazole and pantoprazole sulfone (PS) (n = 5).
Concentration (μg/mL)

Pantoprazole Recovery ± SD (%)

Pantoprazole RSD (%)

PS Recovery ± SD (%)

PS RSD (%)

0.03
0.30
3.0
30

101 ± 1.1
99 ± 2.3
97 ± 2.9
99 ± 4.9

1.1
2.4
2.9
4.9

101 ± 6.4
89 ± 2.1
94 ± 4.0
101 ± 4.2

6.3
2.3
4.2
4.5

n: number of samples; SD: standard deviation; RSD: relative standard deviation.

accuracy of the method for both the parent compound and its metabolite
ranged from 100 to 113%. The QC sample values for both accuracy
and precision are in the acceptable ranges based on FDA Bioanalytical
guidelines.
3.3.4. Stability
Extracted QC samples were stored in a refrigerator (4 0 C) for 24 h and
in the autosampler for 24 h. Analysis indicated a loss for pantoprazole
of 27% and 13% while the metabolite experienced similar results (25%
after refrigeration and 10% in the autosampler). This would indicate
that extracted samples that have been stored for 24 h should probably
not be analyzed and caution should be used in analyzing large sample
batches. There was no loss of pantoprazole or its metabolite after three
freeze/thaw cycles.
3.3.5. Pharmacokinetic study
This method has been used in the analysis of samples from a pharmacokinetic (PK) study in goats (University of Tennessee College of Veterinary Medicine study protocol 2825–0221) after intravenous administration [17]. A plasma concentration time curve from one of the goats
administered 1 mg/kg intravenously is pictured in Fig. 3. The pantoprazole area under the concentration time curve from 0 to inﬁnity (AUC0-∞ )
was 0.895 h∙μg/mL the half-life of elimination (t 21 ) was 1 h, the clearance (Cl) was 1.17 mL/kg/h while the volume of distribution at steady
state (Vdss ) was 0.43 L/kg. The PK parameters for pantoprazole sulfone were AUC0-∞ 0.160 h∙μg/mL, t 21 0.46 h, maximum concentration
(Cmax ) 0.14 μg/mL and time to maximum concentration (Tmax ) 0.33 h.
Pharmacokinetic parameters were generated from a commercial software program (Phoenix 64 WinNonlin 8.1, Pharsight Corp, Mountain
View, CA).

Fig. 3. Goat plasma concentration time curve for intravenously administered
pantoprazole (1 mg/kg). Pantoprazole (○) and pantoprazole sulfone (□).

recovery of greater than 90% for both the metabolite and pantoprazole.
The amounts of chloroform were varied between 1 and 3 mL in order to
determine the appropriate amount and the addition of 1 mL produced
the desired results.
3.3. Method validation
3.3.1. Selectivity
Plasma from untreated goats was extracted and no endogenous components aﬀected the elution of pantoprazole, pantoprazole sulfone or
tinidazole (Fig. 2A). Plasma for the validation process came from six
separate sources. Also illustrated in Fig. 2 are chromatograms for a (B)
0.5 μg/mL standard and (C) a goat sample 20 min after administering an
intravenous dose of 1 mg/kg pantoprazole. Elution times for tinidazole,
pantoprazole sulfone and pantoprazole were 2.78, 4.49 and 5.86 min.

4. Conclusion
This is a fully validated method for the quantiﬁcation of pantoprazole and its metabolite in plasma samples. It was validated based on
FDA Bioanalytical guidelines and has met those criteria. It would be
useful for the analysis of a wide range of drug concentrations and can
be applied to pharmacokinetic studies. The lower sample volume is an
advantage that could make it beneﬁcial for studies involving smaller animals. The method presented was used in the analysis of pantoprazole
samples from a pharmacokinetic study conducted at this facility and
could be suitable for additional species. However, it may require some
additional validation.

3.3.2. Linearity, calibration curve and LLOQ
The peak area ratio versus concentration was linear for the concentration range used (0.01–50 μg/mL) with a correlation coeﬃcient of
greater than 0.99 for both pantoprazole and its metabolite. The linear
relationship for pantoprazole sulfone could be deﬁned by the equation
y = 0.1473x + 0.0075 while the relationship for pantoprazole could be
deﬁned by the equation y = 0.1507x + 0.0271. The x represents the
plasma concentration of the metabolite or pantoprazole in plasma.
The LLOQ of the method was 0.01 μg/ml, which represents a peak
roughly ten times baseline noise. This is sensitive enough for use in pharmacokinetic studies.
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3.3.3. Recovery accuracy and precision
The recoveries of pantoprazole and its metabolite (Table 2) ranged
from 97 to 101% and 89 to 101%, respectively. The average recovery for
tinidazole was 99% ± 5.9%. The intra and inter assay precision values
for pantoprazole ranged from 3.4 to 10% and 2.3 to 9.8% while the
metabolite ranged from 3.3 to 8.7% and 3.3 to 7.5% (Table 1). The
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